Enzene Biosciences, a global CDMO known for its flagship fully-connected continuous manufacturing platform (EnzeneX), has launched a new Drug Discovery Division—further expanding its breadth of services to the biotech industry and complementing its EnzeneX-equipped biologics manufacturing site, which will open later this summer in the U.S.
 
Enzene is introducing its new discovery arm to provide end-to-end integrated discovery services in response to the rapidly growing industry demands. The discovery offerings will include antibody services (target validation, discovery and engineering), reagent production ranging from custom peptides & proteins to advanced modalities like plasmids, RNA and exosomes, and multi-platforms assays services.
 
While financial details remain undisclosed, the new Discovery Division will be located at Enzene’s Pune facility, with new state-of-the-art discovery laboratories set to be operational by July and further expansions planned later in the year.
 
By integrating its existing capabilities in bioprocessing, product development, and commercialization with the new discovery capabilities, Enzene aims to emerge as a fully integrated, one-stop solution provider empowering biopharmaceutical innovators to expedite their journey from discovery to commercialization.
 
“There is a global shortage of biology services, and our clients are increasingly looking to collaborate with us much earlier in the discovery phase to expedite their progress to IND and beyond. We anticipate even greater demand for these services in the coming year as the resurgence in biotech funding leads to more targets entering discovery – with contract R&D empowering them to advance more targets simultaneously,” commented Himanshu Gadgil, CEO of Enzene Biosciences.
 
Enzene will open its $50 million New Jersey site this summer, which will also be the first site in the USA with a fully connected continuous manufacturing platform and will be staffed by over 300 personnel. The CDMO has available capacity to produce complex proteins along with standard modalities via both CHO and mammalian cell lines.